GlaxoSmithKline (GSK) announced that the United States FDA granted accelerated approval for Promacta (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
The details can be read here.
No comments:
Post a Comment